Imugene Receives $2 Million R&D Refund to Support Azer-Cel Trial
IMU: $0.035 -2.78% · MC: $20M
Imugene has received an approximately $2 million R&D tax refund for FY2026, which it says will assist patient recruitment in the BTK-inhibitor combination cohort of its Phase 1b azer-cel study.

Comments